Hemagen Diagnostics Stock Revenue
| HMGNDelisted Stock | USD 0.0001 0.00 0.00% |
Hemagen Diagnostics fundamentals help investors to digest information that contributes to Hemagen Diagnostics' financial success or failures. It also enables traders to predict the movement of Hemagen Pink Sheet. The fundamental analysis module provides a way to measure Hemagen Diagnostics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Hemagen Diagnostics pink sheet.
Hemagen |
Hemagen Diagnostics Company Revenue Analysis
Hemagen Diagnostics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Hemagen Diagnostics Revenue | 4.04 M |
Most of Hemagen Diagnostics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Hemagen Diagnostics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
CompetitionBased on the latest financial disclosure, Hemagen Diagnostics reported 4.04 M of revenue. This is 99.95% lower than that of the Health Care Equipment & Supplies sector and 99.46% lower than that of the Health Care industry. The revenue for all United States stocks is 99.96% higher than that of the company.
Hemagen Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Hemagen Diagnostics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Hemagen Diagnostics could also be used in its relative valuation, which is a method of valuing Hemagen Diagnostics by comparing valuation metrics of similar companies.Hemagen Diagnostics is currently under evaluation in revenue category among related companies.
Hemagen Fundamentals
| Return On Asset | -0.1 | ||||
| Profit Margin | (0.22) % | ||||
| Operating Margin | (0.11) % | ||||
| Current Valuation | 441.76 K | ||||
| Shares Outstanding | 15.5 M | ||||
| Price To Earning | (0.17) X | ||||
| Price To Sales | 0.1 X | ||||
| Revenue | 4.04 M | ||||
| Gross Profit | 1.61 M | ||||
| EBITDA | (273.66 K) | ||||
| Net Income | (907.32 K) | ||||
| Cash And Equivalents | 66.29 K | ||||
| Current Ratio | 1.07 X | ||||
| Book Value Per Share | (0.23) X | ||||
| Cash Flow From Operations | (358.69 K) | ||||
| Earnings Per Share | (0.06) X | ||||
| Number Of Employees | 15 | ||||
| Beta | 0.39 | ||||
| Market Capitalization | 387.51 K | ||||
| Total Asset | 2.44 M | ||||
| Retained Earnings | (26.68 M) | ||||
| Working Capital | 145 K | ||||
| Current Asset | 2.1 M | ||||
| Current Liabilities | 1.95 M | ||||
| Z Score | -13.0 | ||||
| Net Asset | 2.44 M |
About Hemagen Diagnostics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Hemagen Diagnostics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Hemagen Diagnostics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Hemagen Diagnostics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Hemagen Diagnostics information on this page should be used as a complementary analysis to other Hemagen Diagnostics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Hemagen Pink Sheet
If you are still planning to invest in Hemagen Diagnostics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Hemagen Diagnostics' history and understand the potential risks before investing.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets |